Corporate Greed: The Cause of the Opioid Crisis

Clare Ongera

Clare Ongera

Research Associate | BIO

Opioids are the most commonly used and effective analgesic treatments for severe pain, but they have recently come under scrutiny owning to epidemic levels of abuse and overdose. In 2017, there were 70,237 drug overdose deaths in the United States.

How did we get here?

In the late 1990s, pharmaceutical companies reassured the medical community that patients would not become addicted to opioid pain relievers and healthcare providers began to prescribe them at greater rates. Increased prescription of opioid medications led to widespread misuse of both prescription and non-prescription opioids before it became clear that these medications could indeed be highly addictive.

Why did this happen?

There are two main causes for the increase in opioid prescription and addiction:

 1. Pharmaceutical Lies: Pharmaceutical companies telling physicians opioid pain relievers are safe, effective and non-addictive (false advertising)

It is impossible to talk about the causes of America’s opioid epidemic without pointing to the manufacturers and distributors that marketed and proliferated dangerous opioid painkillers.

When Purdue Pharma introduced OxyContin in 1996, it was aggressively marketed and highly promoted. Sales grew from 48 million in 1996 to almost 1.1 billion in 2000. The high availability of OxyContin correlated with increased abuse, diversion and addiction. By 2004 OxyContin had become a leading drug of abuse in the United States.

Purdue’s marketing plan involved:

  • creating a database that would help identify physician who frequently prescribed opioids and those with large number of chronic-pain patients.
  • a lucrative bonus system that encouraged sales representatives to increase sales of OxyContin in their territories
  • promoting the use of opioids for use in the non-malignant (non-cancerous) pain market. This was a larger market than that for cancer-related pain and constituted 86% of the total opioid market in 1999.
  • training sales representatives to carry the dishonest message that the risk of addiction was less than one percent.

A few years after misrepresenting the risk of addiction, Purdue Fredrick Company along with 3 other executives pled guilty to criminal charges of misbranding OxyContin and they paid 634 million in fines in 2007.

 2. Conditioning Medical Professionals: Doctors told to treat pain more aggressively

In 2001, the Joint Commission rolled out its Pain Management Standards, which helped grow the idea that pain is a “fifth vital sign”. It required healthcare providers to ask every patient about their pain, given the perception at the time was that pain was underassessed and undertreated. The joint Commission partnered with Purdue pharma to set these pain management standards. Advocates have urged the Joint Commission and Center for Medicare and Medicaid Services (CMS) to scrap policies that could lead to opioid over prescribing.

 

Consequences

Multibillion-dollar drug companies like Purdue and many others have avoided accountability for opioid crisis until, perhaps, now.

    • Earlier this year, Purdue Pharma, the maker of OxyContin agreed to pay $270 million in a settlement with Oklahoma. Teva, another pharmaceutical company agreed to a $85 million settlement with the state.
  • On August 26th, 2019 a court ruled that Johnson and Johnson helped fuel Oklahoma’s opioid epidemic and ordered the company to pay more than 570 million to help address the crisis. It is the first time a trial court has held a drug maker accountable for the nation’s opioid crisis, which has contributed to the more than 700,000 drug overdose deaths in the US since 1999.

There are now about 2,000 lawsuits, largely from various levels of government, consolidated with a federal judge in Cleveland in an attempt to reach a single landmark legal resolution to the opioid epidemic – one that may force opioid makers like Purdue and Johnson and Johnson, but also distributors like CVS and Walgreens to shell out even more to help pay for the drug addiction and overdose crisis.

  • On September 11th, 2019, top legal officials in 27 states and territories and lawyers from more than 2,000 cities and counties announced they had agreed to a tentative multi-billion-dollar settlement with Purdue Pharma. At least 20 other state attorneys general who are suing the drug company have not agreed with the deal, and vow to pursue Purdue Pharma to try to recover vast sums that their governments spent on treatment and care for recovering patients. The settlement did not include admission of wrongdoing.

Check back tomorrow for possible solutions to the opioid crisis…

Clare Ongera

Research Associate

Ms. Clare Ongera works at Focus for Health as a Research Associate. She graduated from Rutgers University Graduate School of Biomedical Sciences (GSBS) in Newark where she spent a year as a researcher at the Laboratory for Regenerative Neurobiology at the Cancer Research Center (CANCT). Prior to her work at the Cancer Research Center, she worked for Rutgers School of Health Professions (SHP) as a Graduate Researcher for the Facilities and IT departments. She completed her undergraduate degree in Biology at Rutgers New Brunswick NJ. Ms. Ongera is an active member of the lifelong network of alumnae of Rutgers Douglass Residential College.

One Comment

Jefferson C.

Excellent article! It’s truly unfortunate that these big pharmaceutical companies are engaged in such marketing tactics, which are increasingly becoming a significant detriment to the most vulnerable patients.

Reply

Join the Conversation

Your email address will not be published. Required fields are marked *